LCID
Lucid Group, Inc.
LCID has the edge over XPOF overall, supported by stronger fundamentals and lower modeled downside.
XPOF
Xponential Fitness, Inc.
XPOF offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
XPOF Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Weak | |
| Weak |
XPOF's revenue is currently healthy, and its profitability is stable, but its cash flow and balance sheet are weak.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
XPOF PE Valuation
XPOF has no meaningful PE right now: it lost money over the past year.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
XPOF Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect XPOF's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
XPOF Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.49 | — |
| Q3 2026 | -$1.20 | +$0.48 |
| Q2 2026 | -$1.48 | +$0.31 |
| Q1 2026 | -$1.39 | +$0.68 |
| Q4 2025 | -$1.47 | +$0.80 |
| Q3 2025 | -$1.68 | -$0.53 |
XPOF has the edge over LCID on earnings, with more consistent year-over-year improvement.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over XPOF on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
XPOF Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.9M | +23% |
| Q2 2026 | $2.7M | -1% |
| Q1 2026 | $2.2M | -17% |
| Q4 2025 | $3.4M | -7.3% |
| Q3 2025 | $2.4M | -37% |
| Q2 2025 | $2.7M | -22% |
| Q1 2025 | $2.6M | -14% |
| Q4 2024 | $3.6M | +18% |
XPOF's revenue is recovering but still below its 2022 peak: $3M last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 664% | +514 points |
| Q2 2026 | 352% | -191 points |
| Q1 2026 | 603% | +233 points |
| Q4 2025 | -245% | +1194 points |
| Q3 2025 | 150% | +318 points |
| Q2 2025 | 543% | +612 points |
| Q1 2025 | 370% | +128 points |
| Q4 2024 | -1439% | -1535 points |
XPOF has the edge over LCID on profitability, with a higher operating margin.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
XPOF Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.1M | -50% |
| Q2 2026 | -$4.3M | -533% |
| Q1 2026 | -$22.2M | -514% |
| Q4 2025 | $10.2M | +1077% |
| Q3 2025 | $8.2M | +143% |
| Q2 2025 | $996K | +14% |
| Q1 2025 | $5.4M | +191% |
| Q4 2024 | $864K | +$4.9M |
XPOF has the edge over LCID on cash flow, with more consistent year-over-year improvement.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has the edge over XPOF on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
XPOF Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +17% | +7.2M shares |
| 1 year | +40% | +14.2M shares |
| 3 years | +60% | +18.5M shares |
XPOF has 49M diluted shares, up 40% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q4 2023 | — |
| Q4 2022 | — |
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
XPOF Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 11.5x | High |
| Q2 2026 | 17.1x | High |
| Q1 2026 | 14.0x | High |
| Q4 2025 | 14.4x | High |
| Q3 2024 | 16.4x | High |
| Q2 2024 | 9.1x | High |
| Q1 2024 | 4.2x | High |
| Q4 2023 | 5.1x | High |
XPOF's net debt is about 11 years of its operating earnings (EBITDA), down from 16 years a year ago.
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
XPOF Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.2 | Neutral |
| Stochastic | 35.7 | Neutral |
XPOF's weekly RSI is 44 (neutral) and its Stochastic is 36 (neutral).
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
XPOF PE vs Consumer Cyclical Sector
XPOF has no meaningful PE right now: it lost money over the past year.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
XPOF Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.50 | 2.9% above |
| 20 week MA | $5.11 | 9.4% below |
| 50 week MA | $6.17 | 25% below |
| 100 week MA | $8.00 | 42% below |
| 200 week MA | $12.8 | 64% below |
XPOF has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.
XPOF Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $12.3 | $20.6 | +68% |
| 2022 | $20.6 | $22.9 | +11% |
| 2023 | $22.9 | $12.9 | -44% |
| 2024 | $12.9 | $12.8 | -0.4% |
| 2025 | $12.8 | $8.74 | -32% |
| 2026 YTD | $8.74 | $4.63 | -47% |
XPOF has the edge over LCID on returns for 2026, with the stronger performance.